Peptidomimetics with photocontrolled biological activity
A “hot” area of research – photopharmacology – have been pursued at the international forefront, together with scientists from the University of Cambridge (UK), Karlsruhe Institute of Technology (Germany), Latvian Institute of Organic Synthesis (Latvia), VU University Medical Center (the Netherlands). Photopharmacology is a rapidly expanding and highly innovative area of research focused on the development and application of photocontrollable drugs.
Diarylethene-based photo-isomerizable cyclic peptides (like GS-Sw(FP)) are a promising source of the drugs for photopharmacology, they opened a new class of agents, whose biological activity and toxicity can be “switched ON” and “OFF” by visible light in living organisms. Patents on the technology were licensed to the company Lumobiotics which is carrying out corresponding preclinical research.
Selected publications and patents:
European Patent No.2958934 “Peptidomimetics possessing photo-controlled biological activity”
US Patent No.9481712 “Peptidomimetics possessing photo-controlled biological activity”
- Oleg Babii, Sergii Afonin, Christian Diel, Marcel Huhn, Jennifer Dommermuth, Tim Schober, Serhii Koniev, Andrii Hrebonkin, Alexander Nesterov-Mueller, Igor V. Komarov, Anne S. Ulrich. Angew. Chem. Int. Ed., 2021, 60:21789-21794, DOI 10.1002/anie.202108847
- Oleg Babii, Sergii Afonin, Tim Schober, Liudmyla V Garmanchuk, Liudmyla I Ostapchenko, Volodymyr Yurchenko, Sergey Zozulya, Oleksandr Tarasov, Iryna Pishel, Anne S Ulrich, Igor V Komarov. Future Drug. Discov. 2020, DOI 10.4155/fdd-2019-0033
- Oleg Babii, Sergii Afonin, Aleksandr Yu. Ishchenko, Tim Schober, Anatoliy O. Negelia, Ganna M. Tolstanova, Liudmyla V. Garmanchuk, Liudmyla I. Ostapchenko, Igor V. Komarov, Anne S. Ulrich. J. Med. Chem., 2018, 61:10793–10813, DOI: 10.1021/acs.jmedchem.8b01428